Showing results (121-130 of 148) with videos related to
Sort By:
Pageof 15
Cancers|March 12, 2020
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast CancerClaudio Vernieri, Michele Prisciandaro, Federico Nichetti, et al.Oncotarget|December 20, 2015
Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125bElisabetta Vergani, Lorenza Di Guardo, Matteo Dugo, et al.The Journal of Investigative Dermatology|June 1, 2022
Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional ProfilesElisabetta Vergani, Adele Busico, Matteo Dugo, et al.Cancer Research|January 8, 2014
Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progressionViviana Vallacchi, Elisabetta Vergani, Chiara Camisaschi, et al.Journal of Hepatology|February 28, 2026
Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL)Sherrie Bhoori, Licia Rivoltini, David J Pinato, et al.Journal for Immunotherapy of Cancer|February 16, 2021
Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patientsVeronica Huber, Lorenza Di Guardo, Luca Lalli, et al.Cancer Immunology, Immunotherapy : CII|October 11, 2005
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patientsLorenzo Pilla, Roberto Patuzzo, Licia Rivoltini, et al.Journal of Translational Medicine|January 6, 2024
Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer CentresMatteo Pallocca, Ivan Molineris, Enrico Berrino, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptidesPaola Filipazzi, Lorenzo Pilla, Luigi Mariani, et al.Cell Communication and Signaling : CCS|September 24, 2020
miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediatorsElisabetta Vergani, Matteo Dugo, Mara Cossa, et al.Pageof 15